Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERMIT: Cangrelor vs Ticagrelor Alone in STEMI Patients with High Platelet Reactivity
NCT04927949Phase 4Completed
- Sponsor
- CHU Caen Normandie
- Start
- Jun 2021
- Primary completion
- Mar 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised trial of cangrelor in ST elevation myocardial infarction (STEMI) (3 arms), sponsored by CHU Caen Normandie. Primary endpoint: Grade of myocardial blush. Started Jun 2021; status: completed.
02
Drugs
cangrelor
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04927949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927949.